A table in the Outlook article 'Nanotechnology: Carrying drugs' (Nature 491 (suppl. 7425), S58–S60; 2012) wrongly stated that Cerulean Pharma's drug CRLX101 is in phase I trials. In fact, it has been in phase II trials since mid-2012. The table also incorrectly gave the company name as “Cerulean Pharmaceuticals”.
Additional information
The online version of the original article can be found at 10.1038/491S58a
Rights and permissions
About this article
Cite this article
Correction. Nature 494, 176 (2013). https://doi.org/10.1038/494176f
Published:
Issue Date:
DOI: https://doi.org/10.1038/494176f
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
